H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) shares fell 49.5% during trading on Friday . The stock traded as low as $2.02 and last traded at $2.02. 400 shares were traded during trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Performance
The stock’s 50-day moving average is $2.02 and its 200-day moving average is $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Recommended Stories
- Five stocks we like better than H-CYTE
- Palantir and Dell Build an AI OS for the Paranoid
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
